<DOC>
	<DOCNO>NCT02311218</DOCNO>
	<brief_summary>In February 2013 , 44 healthy adult recruit randomized daily intake lozenge without Lactobacillus reuteri strain DSM 17938 PTA 5289 12 week . The effect Lactobacillus reuteri strain oral microbial composition monitor , 4 , 8 12 week 1 6 month exposure complete . For purpose saliva tooth plaque collect . Of 44 included subject , 41 complete study . The used Lactobacillus reuteri contain lozenge commercially available identical placebo lozenge obtain manufacturer . The study product well tolerated observe side effect . Compliance excellent . The investigator ' primary outcome determine whether daily intake Lactobacillus reuteri strain DSM 17938 PTA 5289 12 week alters tooth colonize bacterial plaque composition determine multiplex sequencing technique . Effects put relation general knowledge bacterial profile associate risk develop dental caries periodontitis .</brief_summary>
	<brief_title>Probiotic Lactobacillus Reuteri Oral Microbiota</brief_title>
	<detailed_description>Ethics statement The study approve Regional Ethical Review Board Umeå , Sweden ( Dnr 2011-380-31M ) conduct accord principle express Declaration Helsinki . Written inform consent obtain participant . Subjects study design Healthy adult volunteer , age 20-66 year , among student employee Faculty Medicine , Umeå University , Sweden recruit double-blind , randomize control trial ( RCT ) advertisement . Inclusion criteria self-reported healthy status use antibiotic probiotic product 3 month prior study . Based previous study regard persistence probiotic strain [ 31,32 ] , recruitment goal least 15 people per study group . Forty-four volunteer , none use tobacco product , recruit randomly allocate either test ( n = 22 ) placebo group ( n = 22 ; Figure S1 ) . Participants ask allow 2 lozenge per day slowly melt mouth circulate dissolve tablet content around mouth . One lozenge take morning 1 even 12 week . The test lozenge contain L. reuteri ( DSM 17938 PTA 5289 ; 108 CFU per strain ; BioGaia AB , Stockholm , Sweden ) , isomalt , hydrogenate palm oil , peppermint menthol flavoring , peppermint oil , sucralose ( http : //www.biogaia.com/product/biogaia-prodentis-oral-lozenges ) . The placebo lozenges identical test lozenge appearance , taste , composition except lactobacillus . Compliance monitor percentage lozenge consume total assigned number . The remain lozenge count container return monthly refill assess factor . Compliance consider acceptable ≤15 % lozenge remain . Participants ask abstain oral hygiene 48 h consume food least 4 h sample . Participants also instruct eat probiotic product throughout study period . Saliva biofilm sample Saliva tooth biofilm sample obtain immediately ( baseline ) 4 , 8 , 12 week L. reuteri supplementation ( Figure S1 ) . Follow-up sample collect 1 6 month supplementation terminate . Furthermore , whole stimulate saliva ( ~5 mL ) generate chew 1 g paraffin collect ice-chilled sterile test tube . One milliliter saliva use cultural analysis , remain saliva centrifuge 3,500 × g 10 min 4°C . The pellet store −80°C DNA extraction strain-specific PCR reaction . For pyrosequencing analysis , pool supragingival plaque collect sterilized toothpick transfer Eppendorf tube ( Sarstedt , Nümbrecht , Germany ) contain 200 µL TE-buffer ( 10 mM Tris , 1 mM EDTA , pH 7.6 ) . The sample store −80°C DNA extraction . Identification lactobacilli culture PCR Aliquots saliva plat onto Rogosa agar ( Merck , Darmstadt , Germany ) obtain Lactobacillus count selective agar tentative identification L. reuteri ( DSM 17938 PTA 5289 ) strain [ 33 ] . All plat anaerobically incubated 37°C 48-72 h , except L. reuteri PTA 5289 , anaerobically incubate 40°C 72 h. DNA extract saliva pellet describe [ 34 ] . L. reuteri DSM 17938 PTA 5289-specific PCR identify use KAPA2G Robust HotStart PCR Ready Mix ( 2× ) ( Kapa Biosystems , Boston , MA , USA ) strain-specific primer [ 31 ] . Briefly , 2 µL DNA extract add total reaction volume 25 µL ( contain 12.5 µL master mix primer pair concentration 0.5 µM ) . PCR condition 95°C 3 min ; 40 cycle 95°C 15 , 60°C 15 , 72°C 30 ; 72°C 5 min . PCR product verify electrophoresis 2 % agarose gel allow run 80 min 120 V 0.5× TBE ( Tris/Borate/EDTA ) buffer , pH 8.3 , follow ethidium bromide ( 0.2 µg/µL ) staining . Pyrosequencing analysis For 454 pyrosequencing analysis , 16 subject randomly select among test ( n = 8 ) control ( n = 8 ) subject ( Figure S1 ) . DNA extract baseline , 12-week exposure , 1-month follow-up tooth biofilm sample previously describe [ 34 ] . The V3-V4 hypervariable region 16S rRNA gene amplify via PCR use forward primer 347F reverse primer 803R [ 35 ] . For sample identification , fusion primer create primer unique barcode sequence accord Roche guideline experimental amplicon design ( www.454.com ) . DNA amplify follow run condition : initial denaturation 94°C 3 min ; 30 cycle 94ºC 15 , 58ºC 15 , 72ºC 30 ; final extension 72ºC 8 min . Amplicon process 454 sequence conduct Lund University Sequencing Facility ( Faculty Science , Lund , Sweden ) . After amplicon clean remove short fragment ( Agencourt AMPure XP ; Beckman Coulter , Brea , CA , USA ) inspection ( DNA 1000 kit 2100 Bioanalyzer ; Agilent Technologies , Palo Alto , CA , USA ) , amplicons quantify ( Quant-iT d DNA assay kit ; Invitrogen , Carlsbad , CA , USA Quantifluor fluorometer ; Promega , Madison , WI , USA ) dilute obtain total 107 copies/μL . Titration library production ( target : 10 % -15 % enrichment ) perform use emulsion PCR Lib-A kit ( Roche Diagnostics , Branford , CT , USA ) . DNA-positive bead enrich , count ( Innovatis CASY particle counter ; Roche Innovatis , Bielefeld , Germany ) , process ( XLR70 sequence kit ; Roche Diagnostics ) , load onto picotiter plate pyrosequencing 454 Life Sciences Genome Sequencer FLX+ machine ( Roche Applied Sciences ; Penzberg , Germany ) . Data processing Subject characteristic , compliance , culture data process use SPSS ( version 22.0 ; IBM Corporation , Armonk , NY , USA ) . Descriptive statistic , mean [ 95 % confidence interval ( CI ) ] proportion distribution calculate . Differences group test parametric non-parametric test depend data measurement distribution level . P &lt; 0.05 consider statistically significant . Sequences minimum length 300 base pair primer sequence removal , correct barcode sequence , maximum 1 incorrect base pair primer sequence , compliance default quality criterion homopolymers quality score Quantitative Insights Microbial Ecology ( QIIME ) [ 36 ] software package ( version 1.8.0 ) retain analysis . Any sequence beyond reversed primer remove . Sequences begin reverse primer reverse complement . Sequences cluster operational taxonomic unit ( OTUs ) sequence similarity 97 % 16S rRNA chimera-checked Greengene database ( date May 2013 ) [ 37 ] use USEARCH [ 38 ] . OTUs single sequence remove . One representative sequence per remain OTU taxonomically assign name unnamed cultivable specie uncultivable phylotype ≥98.5 % identity use HOMD 16S rRNA RefSeq , version 12.0 ( http : //www.homd.org ) [ 28 ] . Rarefaction curve calculate compare microbial richness [ 39 ] . Principal coordinate analysis ( PCoA ) apply evaluate phylogenetic beta diversity [ 40 ] bacterial profile different time point . Multivariate partial least-square analysis ( PLS ) modeling ( SIMCA P+ , version 12.0 ; Umetrics AB , Umeå , Sweden ) perform search microbiota structure relate L. reuteri consumption ( y-variables ) [ 41,42 ] . Tested model include pyrosequencing data lactobacilli streptococci culture PCR data add . Variables autoscaled unit variance cross-validated Y prediction calculate . Subject cluster display score load plot , importance x-variable displayed load plot . Variables , 95 % CI PLS correlation coefficient inlude zero consider statistically significant [ 42 ] . The Q2 value yield capacity x-variables predict outcome ( test placebo group allocation ) . Univariate analysis single taxon apply combination small group high number repeat test .</detailed_description>
	<mesh_term>Dental Plaque</mesh_term>
	<criteria>Adult , healthy , antibiotic treatment intake probiotic product late 3 month Acute chronic disease recruitment , medication .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>oral , microbiota , lactobacillus reuteri ,</keyword>
</DOC>